Results from the BOLDER II ( BipOLar DepRession ) study have underlined the potential for Seroquel ( Quetiapine ) in the treatment of patients with major depressive episodes associated with bipolar disorder.

In BOLDER II, Seroquel 300mg and 600mg doses achieved a statistically significant reduction in levels of bipolar depression compared with placebo ( p<0.001 ), as measured by the change from baseline in MADRS total score.

BOLDER II, an eight week, multi-centre, placebo-controlled study, reinforces the findings of the landmark BOLDER I study published in American Journal of Psychiatry in July 2005, which first indicated a significant effect for Seroquel in treating major depressive episodes associated with bipolar disorder.

In BOLDER II, the significant reduction in MADRS total score was seen both in patients with bipolar I and bipolar II disorder, in patients with or without a rapid cycling course of illness, and as early as week one after randomisation.
Significant improvements were also seen compared with placebo in the various secondary study endpoints among Seroquel-treated patients, including reduction of anxiety symptoms. In addition, more than half ( 53% ) of patients receiving Seroquel achieved remission from their bipolar depression symptoms.

Seroquel was shown to be well tolerated in BOLDER II with a similar safety profile seen to that in BOLDER I.
The rate of serious adverse events was low and comparable in all treated groups.
The most common adverse events reported in the trial were dry mouth, sedation, somnolence, dizziness and constipation, and there was a low incidence of treatment-emergent mania in the Seroquel-treated groups.

As in BOLDER I, there was a low incidence of EPS ( extrapyramidal symptoms ) and minimal weight change reported in the study.

Joseph Calabrese, co-director of the National Institute of Mental Health Bipolar Research Center at University Hospitals of Cleveland and Case Western Reserve University says: " Patients with bipolar depression are underserved and understudied. The findings from the BOLDER II study are very encouraging and support the findings of BOLDER I, in showing the potential of Seroquel, as monotherapy, for the acute treatment for bipolar depression. Each of these two studies represent the largest placebo-controlled short-term studies ever conducted in bipolar depression. The beneficial risk:benefit profile of Seroquel seen in both studies could offer an important therapeutic value for both patients and physicians as we currently have only one FDA-approved therapy to treat depressive episodes associated with bipolar disorder."

Bipolar disorder is a serious mental illness that affects approximately 3-4% of the adult population and is the sixth leading cause of disability in the world.
Patients with bipolar disorder are symptomatic almost half of their lives, and approximately two-thirds of that time is spent in the depressed phase of the illness.
Currently Seroquel is only approved for the treatment of mania associated with bipolar disorder.

Source: AstraZeneca, 2005


XagenaMedicine2005